Clarity Pharmaceuticals bags FDA fast track designation for prostate cancer candidate 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting Fast Track Designation to 67Cu-SAR-bisPSMA, a targeted ... Read More
Telix Pharmaceuticals submits NDA for Pixclara to advance brain cancer imaging
Telix Pharmaceuticals Limited (ASX: TLX) has taken a significant step in the realm of neuro-oncology by submitting a New Drug Application (NDA) to the U.S. ... Read More
Phanes Therapeutics’ PT217 receives FDA orphan drug designation for neuroendocrine carcinoma
Phanes Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing oncology treatments, has achieved a significant milestone with the granting of Orphan Drug Designation (ODD) ... Read More